Last updated: May 4, 2026
Belinostat (PXD101): clinical trials update, market analysis, and projection
What is belinostat and what indications drive the clinical and market picture?
Belinostat is an HDAC inhibitor with U.S. approval for relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one prior therapy. The compound is marketed in the U.S. under the brand name Beleodaq (Eisai).
Regulatory anchor (U.S.)
- Indication: relapsed or refractory PTCL after at least one prior therapy
- FDA approval: 2014
(FDA label entry for Beleodaq indicates PTCL relapsed/refractory population.) [1]
Primary commercial impact channel
- Belinostat’s revenue engine is PTCL, with any expansion depending on whether ongoing programs demonstrate clinical benefit and win label scope.
What is the current clinical-trials status by development area?
Belinostat’s clinical program spans (1) lymphoma, (2) solid tumors in combinations, and (3) earlier-stage mechanistic or biomarker-led work. The most business-relevant question for projection is whether any combination regimens are building a label-expansion case in competitive settings.
Lymphoma
- Core status: PTCL remains the anchor indication due to existing approval.
- Pattern in development: belinostat has been tested in combinations and in other hematologic contexts where HDAC inhibition may synergize with standard chemotherapy or immunotherapies (commonly via altered acetylation and cell-cycle effects).
Solid tumors
- Core status: belinostat is evaluated in combination approaches where HDAC inhibition is used to modulate transcriptional programs and immune signaling.
- Pattern in development: solid tumor programs have historically faced higher attrition due to translation of HDAC biology into durable response; value hinges on biomarker selection and combination partner choice.
Key practical readout for investors and R&D planners
- The pipeline’s economic leverage depends on (a) new phase-2/phase-3 readouts, (b) registrational trial starts, and (c) label-relevant endpoints (ORR, PFS, OS) with a statistical plan that supports regulatory filing.
(Clinical-trial registry and label basis are tied to public sources for trial identifiers and program context.) [2–4]
How do clinical updates translate into valuation leverage?
For belinostat, incremental value is driven by three observable levers:
- Label expansion in PTCL or adjacent lymphoma
- Clinical value is highest when trials target earlier lines, larger subtypes, or maintenance settings with durable PFS/OS benefit.
- Registrational-grade solid tumor strategy
- Value materializes only if belinostat demonstrates consistent efficacy in a defined tumor subtype or biomarker group in combination therapy.
- Operational continuity in commercialization
- Sustained demand in the approved PTCL population supports funding for subsequent trials and reduces the need for rapid monetization.
Market analysis: current demand, competitive landscape, and pricing dynamics
What is the current market position for Beleodaq/belinostat?
Belinostat’s market position is structurally narrower than many on-market oncology drugs because the approved indication is a specific hematologic subgroup (relapsed/refractory PTCL).
Implication
- Growth is typically constrained by:
- PTCL incidence and line-of-therapy progression rates
- competition from other PTCL agents and combination regimens
- payer and guideline uptake
Pricing framework (U.S.)
- Beleodaq pricing is governed by U.S. oncology reimbursement practice (ingredient cost, dose and schedule, patient access programs, and payer formulary placement).
- The label and dosing schedule define cost-per-cycle; market forecasts are therefore sensitive to duration of treatment and discontinuation rates.
Evidence basis for dosing and usage
- The U.S. FDA label includes dosing and administration information and is the reference point used by payers and providers to determine patient-level treatment cost. [1]
Who competes with belinostat in PTCL and related settings?
Belinostat competes in relapsed/refractory PTCL with agents that target distinct pathways (immunomodulation, apoptosis, antibody-mediated mechanisms, and other HDAC or epigenetic approaches where present in the U.S. market).
Competitive variables that matter
- Response durability after multiple prior therapies
- Toxicity tolerability profile
- Ease of administration
- Line-of-therapy placement and guideline inclusion
- Combination uptake where belinostat is not the standard-of-care backbone
Business impact
- Competitive pressure reduces attainable share unless clinical differentiation is clear (for example, superior response rate, deeper responses, or better safety permitting broader use).
Projection: sales outlook under scenarios
What drives a credible forecast model for belinostat?
A projection for belinostat must model:
- Patient pool: relapsed/refractory PTCL eligible for HDAC inhibitor therapy
- Adoption: proportion of eligible patients treated with belinostat based on guideline placement and formulary coverage
- Treatment dynamics: average number of cycles and discontinuation rates
- Net price: launch-to-present discounting and payer rebates
- Pipeline impact: potential label expansion or new line-of-therapy adoption triggered by trial outcomes
Foundational commercialization constraint
- Because the approved indication is narrow, even modest label expansion can move the model materially, while a lack of new approvals keeps growth limited to share gains and market access expansion.
Scenario projection structure (three cases)
Because public sources do not provide a single definitive real-time revenue estimate for Beleodaq, the forecast framework should be constructed from demand drivers and regulatory catalysts:
Base case
- PTCL remains the only reimbursed indication.
- Share changes track modest competitive shifts.
- No new label expansion achieved in the near-term.
Upside case
- Clinical readouts support a label expansion in PTCL (for example, earlier lines or broader subgroup coverage).
- Adoption increases through payer confidence and guideline updates.
Downside case
- Competitive products capture additional share via combinations and improved toxicity profiles.
- No label expansion, leading to flat or declining demand in a finite addressable market.
Forecast sensitivity
- Adoption rate (share) and treatment duration are the top two sensitivity points.
- Pipeline success converts into forecast uplift only if it yields a regulatory pathway that changes standard-of-care placement (not only incremental response).
Strategic implications: what to watch next
Which trial signals matter most for market expansion?
For belinostat, the highest-impact signals are:
- Phase-2 or Phase-3 efficacy with clinically meaningful endpoints (PFS/OS)
- Durable response rates across subgroups relevant to PTCL biology
- Safety allowing combination use without dose-limiting toxicities
- Evidence that supports a regulatory label expansion claim
How to time decision-making
- Investors typically need phase-2-to-registration transition clarity (design, endpoint choice, and statistical powering) to price future sales.
Key Takeaways
- Belinostat is an HDAC inhibitor approved in the U.S. for relapsed or refractory PTCL after at least one prior therapy; commercialization and forecasts hinge on the finite PTCL patient pool and payer access dynamics. [1]
- Clinical value is driven by label expansion probability, because the existing indication is narrow and limits organic growth absent new regulatory wins.
- Market projection is sensitive to adoption and treatment duration, with upside dependent on phase-2/phase-3 signals that change standard-of-care placement rather than only showing activity.
- Competitive pressure in relapsed/refractory PTCL can cap share, so market outcomes track efficacy durability and tolerability relative to alternative regimens.
FAQs
-
What is belinostat approved for in the U.S.?
Relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one prior therapy. [1]
-
What is the brand name of belinostat in the U.S.?
Beleodaq. [1]
-
What is the primary market risk for belinostat?
Limited addressable patient population tied to a narrow approved indication, so growth depends on label expansion and adoption. [1]
-
Which clinical signals would most improve belinostat’s market outlook?
Trials demonstrating durable efficacy with endpoints supporting regulatory label expansion, especially in PTCL settings that shift line-of-therapy adoption. [2–4]
-
Where can current trial details be verified?
Public trial registries and the FDA label provide the most direct references for ongoing study identification and clinical/program context. [1–4]
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). BELEODAQ (belinostat) prescribing information / FDA label. FDA.
[2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: belinostat (search results and study records). ClinicalTrials.gov.
[3] European Medicines Agency. (n.d.). EPAR and product information for belinostat (where available). EMA.
[4] World Health Organization. (n.d.). International Clinical Trials Registry Platform (ICTRP) entries for belinostat. WHO ICTRP.
